Immunogenicity of the anti-IL-17A antibody secukinumab in healthy subjects and patients

被引：0
|
作者：
Klein, U. [1 ]
Liang, E. [1 ]
Vogel, B. [1 ]
Kolbinger, F. [1 ]
Bruin, G. [1 ]
Lloyd, P. [1 ]
机构：
[1] Novartis Inst BioMed Res, Basel, Switzerland
来源：
JOURNAL OF INVESTIGATIVE DERMATOLOGY | 2013年 / 133卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
1012
引用
收藏
页码：S172 / S172
页数：1
相关论文
共 50 条
  • [1] IMMUNOGENICITY OF THE NOVEL ANTI-IL-17A ANTIBODY, SECUKINUMAB, WITH INTRAVENOUS AND SUBCUTANEOUS DOSING REGIMENS IN HEALTHY SUBJECTS AND PATIENTS
    Klein, U.
    Liang, E.
    Vogel, B.
    Kolbinger, F.
    Bruin, G.
    Lloyd, P.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 : 630 - 630
  • [2] Assessment of the immune response to novel Anti-IL-17A antibody, secukinumab, after intravenous and subcutaneous application in healthy subjects and patients
    Klein, U.
    Kolbinger, F.
    Liang, E.
    Vogel, B.
    Bruin, G.
    Lloyd, P.
    ZEITSCHRIFT FUR RHEUMATOLOGIE, 2013, 72 : 134 - 134
  • [3] Challenges of systemic IL-17A quantification in patients treated with secukinumab, an anti-IL-17A antibody
    Calonder, C.
    Helbaj, R.
    Spindeldreher, S.
    Lloyd, P.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2013, 133 : S22 - S22
  • [4] The anti-IL-17A antibody secukinumab does not attenuate ozone-induced airway neutrophilia in healthy volunteers
    Kirsten, Anne
    Watz, Henrik
    Pedersen, Frauke
    Holz, Olaf
    Smith, Rachel
    Bruin, Gerard
    Koehne-Voss, Stephan
    Magnussen, Helgo
    Waltz, David A.
    EUROPEAN RESPIRATORY JOURNAL, 2013, 41 (01) : 239 - 241
  • [5] Secukinumab, a novel anti-IL-17A antibody, exhibits low immunogenicity during long-term treatment in subjects with moderate to severe plaque psoriasis
    Reich, Kristian
    Blauvelt, Andrew
    Armstrong, April
    Fox, Todd
    Huang, Jiaqing
    Bruin, Gerard
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2015, 135 : S15 - S15
  • [6] Secukinumab: The Anti-IL-17A Biologic for the Treatment of Psoriasis
    Fargnoli, Maria Concetta
    CASE REPORTS IN DERMATOLOGY, 2019, 11 : 1 - 3
  • [7] Secukinumab: a review of the anti-IL-17A biologic for the treatment of psoriasis
    Frieder, Jillian
    Kivelevitch, Dario
    Menter, Alan
    THERAPEUTIC ADVANCES IN CHRONIC DISEASE, 2018, 9 (01) : 5 - 21
  • [8] Secukinumab (Anti-IL-17A Therapeutic Antibody) Improves Clinical Outcome for a Mixed Endotype CRS
    Plaas, Mihkel
    Brazovskaja, Agnieska
    Kisand, Kai
    Tserel, Liina
    Peterson, Part
    CLINICAL CASE REPORTS, 2024, 12 (12):
  • [9] Secukinumab, a novel anti-IL-17A antibody, shows low immunogenicity potential in human in vitro assays comparable to other marketed biotherapeutics with low clinical immunogenicity
    Karle, Anette
    Spindeldreher, Sebastian
    Kolbinger, Frank
    MABS, 2016, 8 (03) : 536 - 550
  • [10] Ixekizumab, a novel anti-IL-17A antibody, exhibits low immunogenicity during long-term treatment in patients with psoriasis
    Blauvelt, A.
    Langley, R.
    Leonardi, C.
    Gordon, K.
    Luger, T.
    Ohtsuki, M.
    Nickoloff, B.
    Kerr, L.
    Mallbris, L.
    Reich, K.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2016, 136 (09) : S227 - S227
12345